Signed in
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
Welcome to Pump.fun!
Pump lets anyone create coins, giving everyone equal access to buy and sell from the start. Prices can move quickly, so trade carefully.
By clicking this button, you agree to the Terms and Conditions, Privacy Policy, and certify that you are over 18 years old.
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
Paired with SOL| No holders yet. | ||||||||||
Moderna and Merck announced positive results from the Phase 3 INTerpath-001 trial, where their personalized mRNA vaccine intismeran autogene combined with KEYTRUDA beat KEYTRUDA alone for high-risk melanoma patients.